MyFinsight
Home
Blog
About
Proceeds from issuance of
series c preferred...
$103,639K
Issuance of common stock
in connection with...
$5,350K
(85.12%↑ Y/Y)
Net cash assumed in
the orphai...
-$8,001K
Net cash provided by
financing activities
$108,933K
(651.31%↑ Y/Y)
Net cash provided by
investing activities
$8,001K
(-52.76%↓ Y/Y)
Canceled cashflow
$56K
Net increase in cash
and cash...
$97,818K
(821.59%↑ Y/Y)
Canceled cashflow
$19,116K
Cash settlement of
common warrants
$56K
Acquired in-process
research and development...
$59,000K
Stock based
compensation
$12,093K
(354.80%↑ Y/Y)
Right of use assets,
operating leases and...
-$423K
(-698.11%↓ Y/Y)
Prepaid expenses and
other current assets
-$362K
(38.44%↑ Y/Y)
Accounts payable
$260K
(118.35%↑ Y/Y)
Depreciation and
amortization
$41K
(-38.81%↓ Y/Y)
Net cash used in
operating activities
-$18,887K
(10.13%↑ Y/Y)
Effect of exchange rate
changes on cash
-$229K
(-218.04%↓ Y/Y)
Canceled cashflow
$72,179K
Net income (loss)
-$75,488K
(-142.89%↓ Y/Y)
Accrued expenses and
other current...
-$7,934K
(-837.36%↓ Y/Y)
Change in fair value of
warrants
-$4,507K
(-200.96%↓ Y/Y)
Gain on orphai
acquisition
$1,305K
Gain on settlement of
accounts payable
$1,136K
Other liabilities
-$688K
Other assets
$8K
(-93.39%↓ Y/Y)
Back
Back
Cash Flow
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)
source: myfinsight.com